ProtAffin AG Starts Phase 1 Study for Lead Product PA401 in Inflammatory Lung Disease
6/27/2012 9:24:26 AM
More...
|
ProtAffin AG Releases New Preclinical Data for Lead Anti-inflammatory Product PA401 in Inflammatory Lung Disease
5/22/2012 10:02:08 AM
More...
|
ProtAffin AG Receives Key Grant for Preclinical and Clinical Development of PA401 in Inflammatory Lung Disease
12/14/2011 9:18:17 AM
More...
|
ProtAffin AG Announces Preclinical Data in Multiple Sclerosis for MCP-1 Decoy Program
10/20/2011 12:09:19 PM
More...
|
ProtAffin AG Appoints Dr Mike Bartley as Chief Development Officer
9/26/2011 10:18:31 AM
More...
|
ProtAffin AG Strengthens Supervisory Board
7/25/2011 9:30:28 AM
More...
|
ProtAffin AG Granted Patent in EU for CellJammer(R) Discovery Technology
3/14/2011 10:18:29 AM
More...
|